同期双侧全膝关节置换术中脂质体布比卡因全身安全性研究
前瞻性研究纳入15例同期双侧全膝关节置换术患者,每膝注射含脂质体布比卡因266 mg、0.25%布比卡因75 mg加肾上腺素及生理盐水的关节周围注射液,监测血药浓度及心脏神经毒性事件。平均峰值浓度0.8 μg/mL(范围0.4-1.2 μg/mL),均远低于报道的全身心脏毒性水平2-4 μg/mL,未报告心脏或神经毒性事件。
要点
- 同期双侧全膝关节置换每膝全剂量脂质体布比卡因关节周围注射后,平均峰值血药浓度0.8 μg/mL。
- 所有患者峰值浓度均远低于报道的全身心脏和毒性水平2-4 μg/mL。
- 未报告任何心脏或神经毒性事件。
核心结论
- 同期双侧全膝关节置换术中每膝全剂量脂质体布比卡因关节周围注射是安全的,全身布比卡因水平远低于报道的心脏和神经毒性水平。
研究设计与样本
- 前瞻性研究,纳入15例同期双侧全膝关节置换术患者,每膝注射相同关节周围注射液(脂质体布比卡因20 cc即266 mg、0.25%布比卡因30 cc即75 mg加肾上腺素、生理盐水10 cc),按预定间隔采血至出院,未给予外源性布比卡因,进行药代动力学评价并与布比卡因毒性水平比较,监测麻醉毒性相关不良事件(心脏和神经)。
主要发现
- 15例患者平均年龄60.7岁(范围57-64岁)。
- 平均峰值浓度(Cmax)为0.8 μg/mL(范围0.4-1.2 μg/mL)。
- 所有患者峰值浓度均远低于报道的全身心脏和毒性水平2-4 μg/mL。
- 未报告任何患者发生心脏或神经毒性事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraoperative periarticular injections (PAIs) with local anesthetic are an important component of multimodal pain control in total joint arthroplasty. Liposomal bupivacaine is an extended-release formulation of bupivacaine designed to provide extended pain relief, approved for use in a single surgical site. The systemic safety profile for use in simultaneous bilateral TKA (bTKA) with a full dose in each knee has not been evaluated. The purpose of this study was to determine the safety and pharmacokinetics of bilateral full-dose PAI liposomal bupivacaine in the blood collected in patients undergoing simultaneous bTKA. METHODS: In this prospective study, patients had an identical PAI consisting of 20 cc of liposomal bupivacaine (266 mg), 30 cc of 0.25% bupivacaine (75 mg) with epinephrine, and 10 cc of normal saline injected into each knee during bTKA. Blood samples were collected at predefined intervals until patient discharge. No exogenous bupivacaine was administered. Pharmacokinetic evaluations were subsequently performed and compared to bupivacaine toxicity levels. Patients were monitored for adverse events related to anesthetic toxicity (cardiac and neurologic). RESULTS: Fifteen patients (mean age, 60.7 years; range, 57-64 years) were enrolled in the study. The mean peak level (Cmax) was 0.8 μg/mL (range, 0.4-1.2 μg/mL). All patients were well below the reported systemic cardiac and toxicity levels reported as 2-4 μg/mL. There were no reported cardiac and neurotoxic events in any patients. CONCLUSION: The use of full-dose PAI with liposomal bupivacaine placed into each knee during simultaneous bTKA is safe with systemic bupivacaine levels well below reported cardiac and neurotoxic levels.
引用
- Springer BD, Mason JB, Odum SM, et al. Systemic Safety of Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty. J Arthroplasty. 2017. PMID: 28844768. doi:10.1016/j.arth.2017.07.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。